Vertex Pharmaceuticals revenue
Vertex Pharmaceuticals's revenue was $12.00bn in fiscal 2025, up 8.9% on the year before. Since fiscal 2009 ($102m) it has grown at a compound 34.7% a year. Over the last twelve months it was $12.59bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.1 | 0.1 | 1.4 | 1.5 | 1.2 | 0.6 | 1.0 | 1.7 | 2.5 | 3.0 | 4.2 | 6.2 | 7.6 | 8.9 | 9.9 | 11.0 | 12.0 | 12.6 |
| Growth on the year before | — | +40.7% | +883.9% | +8.3% | −20.6% | −52.1% | +77.9% | +64.9% | +46.2% | +22.5% | +36.6% | +49.1% | +22.1% | +17.9% | +10.5% | +11.7% | +8.9% | — |
| Gross profit | — | — | — | — | — | — | — | 1.5 | 2.2 | 2.6 | 3.6 | 5.5 | 6.7 | 7.9 | 8.6 | 9.5 | 10.4 | 10.8 |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $12B | 98.3% | ▲ 8.6% |
| TRIKAFTAKAFTRIO (part of Products) | $10.3B | 86.2% | ▲ 0.7% |
| ALYFTREK (part of Products) | $838M | 7.0% | — |
| Manufactured Product Other (part of Products) | $820M | 6.9% | ▲ 4.9% |
| CASGEVY | $116M | 1.0% | ▲ 1058.0% |
| JOURNAVX | $59.6M | 0.5% | — |
| Collaborative and Royalty | $30.7M | 0.3% | — |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $7.5B | 62.9% | ▲ 12.9% |
| Outsidethe United States | $4.5B | 37.1% | ▲ 2.7% |
| Europe (part of Outsidethe United States) | $3.5B | 77.7% | ▲ 0.2% |
| Other Countries Outsideofthe United States and Europe (part of Outsidethe United States) | $992M | 22.3% | ▲ 12.6% |
From Vertex Pharmaceuticals's 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Vertex Pharmaceuticals | $12.59bn | 10.2% | 9.8% |
| Biogen | $10.30bn | 2.3% | 1.0% |
| Regeneron Pharmaceuticals | $16.90bn | 18.6% | 8.9% |
| Incyte | $6.01bn | 24.9% | 18.5% |
| Gilead Sciences | $30.99bn | 6.5% | 4.2% |
| Amgen | $38.09bn | 9.1% | 12.7% |
Compare with peers
Head to head: BIIB vs VRTXREGN vs VRTXINCY vs VRTX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies